The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.aw Transient pulmonary opacities/infiltrates (TAPO) (see also under IIj)

I. Interstitial/parenchymal lung disease

I.ba Pulmonary alveolar proteinosis flare/exacerbation

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.q QTc prolongation

LI. Cardiovascular involvement / toxicity

LI.s Heart failure (biventricular, congestive)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.c BAL: An excess proportion of eosinophils

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

LXII. Rechallenge data

LXII.a Rechallenge can lead to near-fatal or fatal relapse of AE/ILD

LXII. Rechallenge data

LXII.e Rechallenge may not necessarily lead to relapse of AE/ILD